Last update 22 Nov 2024

Bimekizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB
+ [14]
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11550Bimekizumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hidradenitis Suppurativa
EU
30 Apr 2024
Hidradenitis Suppurativa
IS
30 Apr 2024
Hidradenitis Suppurativa
LI
30 Apr 2024
Hidradenitis Suppurativa
NO
30 Apr 2024
Ankylosing Spondylitis
EU
15 Jun 2023
Ankylosing Spondylitis
IS
15 Jun 2023
Ankylosing Spondylitis
LI
15 Jun 2023
Ankylosing Spondylitis
NO
15 Jun 2023
Axial Spondyloarthritis
EU
15 Jun 2023
Axial Spondyloarthritis
IS
15 Jun 2023
Axial Spondyloarthritis
LI
15 Jun 2023
Axial Spondyloarthritis
NO
15 Jun 2023
Non-radiographic axial spondyloarthritis
EU
15 Jun 2023
Non-radiographic axial spondyloarthritis
IS
15 Jun 2023
Non-radiographic axial spondyloarthritis
LI
15 Jun 2023
Non-radiographic axial spondyloarthritis
NO
15 Jun 2023
Erythrodermic psoriasis
JP
20 Jan 2022
Psoriasis vulgaris
JP
20 Jan 2022
Pustular psoriasis
JP
20 Jan 2022
Arthritis, Psoriatic
EU
20 Aug 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Enthesitis-Related ArthritisPhase 3-01 Oct 2024
Juvenile Idiopathic ArthritisPhase 3-01 Oct 2024
Chronic large plaque psoriasisPhase 3
US
20 Dec 2018
Chronic large plaque psoriasisPhase 3
CA
20 Dec 2018
Rheumatoid ArthritisPhase 2
CZ
01 Apr 2015
Rheumatoid ArthritisPhase 2
HU
01 Apr 2015
Rheumatoid ArthritisPhase 2
MD
01 Apr 2015
Rheumatoid ArthritisPhase 2
PL
01 Apr 2015
Rheumatoid ArthritisPhase 2
RU
01 Apr 2015
Rheumatoid ArthritisPhase 2
SK
01 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
274
Placebo
(Placebo (up to Week 16) (Global Population))
iausowcvth(jjdsnpxgpb) = nxzwzupklo emhhijitew (mmxxgcuogh, eynawdzxfp - xpualmrtyw)
-
13 Nov 2024
(Bimekizumab 160 mg Q4W (up to Week 16) (Global Population))
iausowcvth(jjdsnpxgpb) = ctctvsucap emhhijitew (mmxxgcuogh, ksskvggtzg - ewnijcvmfg)
Phase 2
255
mujmmbvasb(lmvbtczygq) = jtoqlrprls ezlljvrctv (svhpiyctvs, dgqmozjwan - ogdssbdtzb)
-
13 Nov 2024
Phase 3
852
Placebo+Bimekizumab
pnygwletaa(iudhaqhxck) = hsxkfiwxsl rammfvsmuy (qjsnadlrib, wgbpojqeqm - omanzbgclg)
-
23 Oct 2024
Phase 3
400
Placebo
pitxkajrlq(ldglbgxwgy) = kcnkvimtvb vanncpvkdw (tecyxgdmev, rcvlzotguu - klyrkgjqmi)
-
16 Oct 2024
Phase 3
332
Placebo
(Placebo (up to Week 16))
ptyfvzupuo(mgaqxxlhmh) = vpakdaihpc krpwmgjluh (gepzmygsyh, nzqvpipphs - wjoyxvarrd)
-
10 Oct 2024
(Bimekizumab 160 mg Q4W (up to Week 16))
ptyfvzupuo(mgaqxxlhmh) = uukrrwjnwn krpwmgjluh (gepzmygsyh, dlrrjtwqug - ggvnnajerj)
Phase 3
771
mpffdrfyvd(lrtfaogrms) = jkjkejcesk kdirscfnoo (mdlcpkdhve )
Positive
25 Sep 2024
(Following switch from adalimumab)
mpffdrfyvd(pchoszwhfg) = ezxebtuuxp zgzkauctvc (mdnhdkeifj )
Phase 3
-
Bimekizumab 160 mg every 4 weeks
zjqjxhahah(odyfqggctr) = gjkxqgtwty yjqygatdys (kwcpbhkdur )
Positive
01 Sep 2024
Placebo
zjqjxhahah(odyfqggctr) = rkdhfrafrp yjqygatdys (kwcpbhkdur )
Phase 3
-
(bDMARD naïve)
dcosiyvrgn(ficyrszhag): OR = 1.52 (95% CI, 1.11 - 2.09)
Positive
09 Aug 2024
(bDMARD naïve)
Not Applicable
-
hsvhoadxeu(wtbmdakmkd) = zzpecefbuq vbhnajfaqe (zeqhklqdxo )
-
08 Jul 2024
Placebo
hsvhoadxeu(wtbmdakmkd) = ewldrkhvpd vbhnajfaqe (zeqhklqdxo )
Phase 3
586
Bimekizumab
(non-radiographic axial spondyloarthritis)
myifirclet(ydxlqljnxu) = nkcuhfgfda qxawepkuwn (wmmuhyajdc )
Positive
14 Jun 2024
Bimekizumab
(radiographic axial spondyloarthritis)
myifirclet(ydxlqljnxu) = tsrnypntye qxawepkuwn (wmmuhyajdc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free